indecainide

06/01/1987 - "An oral short-term in-hospital trial in 20 patients (8 patients entered directly from the intravenous short-term trial) was conducted using a single-blind placebo dose titration protocol in which 50 mg of indecainide every 8 hours was increased at 3-day intervals to 75 mg, and then 100 mg every 8 hours depending on the observed change in ventricular arrhythmia frequency by Holter monitoring. "
04/01/1988 - "Indecainide is an effective antiarrhythmic agent in a small number of highly selected patients with serious ventricular arrhythmia, but potentially serious side effects limit its usefulness."
02/01/1985 - "Indecainide is a new (investigational) drug for treating cardiac arrhythmias. "
07/01/1990 - "A total of 8 patients had serious toxicity during the intravenous phase; 6 receiving indecainide experienced increased left ventricular dysfunction or worsening arrhythmia (sustained VT, arrhythmic death) while 2 receiving procainamide developed serious hypotension. "

10/01/1987 - "Mean body weight gain was slightly decreased throughout the study in mice receiving 0.02 or 0.04%, while mice receiving 0.08% indecainide had moderately decreased body weight gain. "

04/01/1988 - "Among seven patients with nonsustained ventricular tachycardia, five had 100% elimination of these events with indecainide and all had greater than or equal to 90% reduction in these events. "
04/01/1988 - "Noninvasive evaluation of indecainide for serious ventricular tachyarrhythmia."
06/01/1987 - "Indecainide was well tolerated, but 2 patients died of ventricular tachyarrhythmias while receiving the drug. "
06/01/1987 - "Antiarrhythmic effects of oral indecainide in patients with ventricular tachyarrhythmias."
01/01/1987 - "Twelve of 15 patients were still inducible for ventricular tachycardia on indecainide. "

07/01/1990 - "In those tolerating indecainide, long-term suppression of ventricular premature complexes (VPCs) and of runs of VT was more consistent than with procainamide. "
09/01/1987 - "Cardiac patients with greater than or equal to 30 ventricular premature complexes per hour hour received indecainide, 50 mg, or quinidine, 200 mg every 6 hours, and the doses were increased until more than 80% suppression was noted, adverse effects occurred or a maximal dose of 100 mg of indecainide or 400 mg of quinidine given every 6 hours. "
11/01/1990 - "Indecainide, a new antiarrhythmic agent classified as type Ic was evaluated in 11 patients with heart disease who had greater than or equal to 30 ventricular premature complexes/hour, moderate-to-marked left ventricular dysfunction, and mean ejection fraction 34% +/- 8%. "

11/01/1990 - "Effect of indecainide in patients with left ventricular dysfunction."
07/01/1990 - "Indecainide has a poor risk-benefit ratio in patients similar to the current population, who have potentially lethal ventricular arrhythmias and severe left ventricular dysfunction."
07/01/1990 - "While indecainide was a potent suppressor of spontaneous VPCs and VT, patients with significant left ventricular dysfunction could not tolerate it. "
10/01/1985 - "The electrophysiologic effects of indecainide, a new class IC antiarrhythmic agent, were assessed in 10 patients with left ventricular dysfunction and inducible sustained ventricular tachycardia. "
11/01/1990 - "Indecainide, a new antiarrhythmic agent classified as type Ic was evaluated in 11 patients with heart disease who had greater than or equal to 30 ventricular premature complexes/hour, moderate-to-marked left ventricular dysfunction, and mean ejection fraction 34% +/- 8%. "